67th Day Of Lockdown

Maharashtra62228269972098 Tamil Nadu2024611313157 Delhi173877846398 Gujarat159448611980 Rajasthan83654855184 Madhya Pradesh76454410334 Uttar Pradesh74454215201 West Bengal48131775302 Bihar3359120915 Andhra Pradesh3330223460 Karnataka278189448 Telangana2256134567 Punjab2197194942 Jammu and Kashmir216487528 Odisha17239779 Haryana172194019 Kerala11515659 Assam9361044 Uttarakhand493794 Jharkhand4621914 Chandigarh3641894 Chhatisgarh364830 Tripura2421650 Himachal Pradesh223634 Goa68370 Puducherry49170 Meghalaya20121 Nagaland1800 Manipur540 Arunachal Pradesh210 Mizoram110 Sikkim100
Science 14 Apr 2020 Heart problems promp ...

Heart problems prompt partial stop of Hydroxychloroquine study for coronavirus

AP
Published Apr 14, 2020, 2:13 pm IST
Updated Apr 14, 2020, 2:13 pm IST
One-fourth of those assigned to get 600 milligrams twice a day for 10 days developed heart rhythm problems, and trends suggested more deaths
Hydroxychloroquine has long been known to have potentially serious side effects, including altering the heartbeat in a way that could lead to sudden death (Photo | AP)
 Hydroxychloroquine has long been known to have potentially serious side effects, including altering the heartbeat in a way that could lead to sudden death (Photo | AP)

Rio de Janeiro: Scientists in Brazil have stopped part of a study of a malaria drug touted as a possible coronavirus treatment after heart rhythm problems developed in one-quarter of people given the higher of two doses being tested.

Chloroquine and a newer, similar drug called hydroxychloroquine, have been pushed by President Donald Trump after some very small, early tests suggested the drugs might curb the virus from entering cells. But the drugs have long been known to have potentially serious side effects, including altering the heartbeat in a way that could lead to sudden death.

 

The Brazilian study, in the Amazonian city of Manaus, had planned to enroll 440 severely ill COVID-19 patients to test two doses of chloroquine, but researchers reported results after only 81 had been treated.

One-fourth of those assigned to get 600 milligrams twice a day for 10 days developed heart rhythm problems, and trends suggested more deaths were occurring in that group, so scientists stopped that part of the study.

The other group was given 450 milligrams twice a day on the first day then once a day for four more days. That is closer to what's being tried in some other studies including some in the United States. It's too soon to know whether that will prove safe or effective; the Brazil study had no comparison group that was getting no treatment.

Only one participant in the Brazil study had no signs of the virus in throat swabs after treatment, researchers noted.

The results from the Brazil study were posted on a research website and have not yet been reviewed by other scientists.

Complicating matters is that all patients in the study also received two antibiotics, ceftriaxone and azithromycin. The latter also can have side effects on the heart. Trump has touted the hydroxychloroquine-azithromycin combination.

Brazil's President Jair Bolsonaro has repeatedly touted the benefits of chloroquine and azithromycin without evidence. He said at one point he heard reports of 100% effectiveness when administered in the correct dosages, zeroed tariffs for import of the drugs, and late last month announced military labs were ramping up their chloroquine production.

Click on Deccan Chronicle Technology and Science for the latest news and reviews. Follow us on Facebook, Twitter

...




ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT